Background: This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed. Trial Registration No: NCT03473223 ( Link Sponsor: CSL Behring Trial Status: recruiting Enrolling Centers: Worldwide: 17400 participants Core Study Team Basel:
© Christian Mueller, 2012 - 2021 │ DisclaimerImprintWebmaster │ Last Update: May 2021
Ina-Maria Ferel Ph.D. Natascha Herr Michael Freese, UP Isabelle Danier Dr. Samyut Shrestha Noemi Glarner Beate Hartmann Ph.D. Michael Kolbe Iris Huber